Calkin et al. reported that rosiglitazone reduces diabetes-related atherosclerosis and that this effect is possibly associated with oxidative stress and inflammation, independent of metabolic effects, unrelated to the insulin dose [49]. The gene discussed is INS; the disease is diabetes mellitus.